A case study is presented of a Don, age 72, was diagnosed with borderline resectable pancreatic adenocarcinoma more than a year ago. Genetic testing indicated a BRCA2 variant. It discusses that he had no evidence of disease for six months until a liver lesion seen on surveillance imaging tested positive for metastatic pancreatic cancer; and mentions that his medical oncologist suggests a clinical trial targeting the BRCA2 variant.